Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

ImmunityBio (IBRX) Tax Provisions (2016 - 2025)

ImmunityBio (IBRX) has disclosed Tax Provisions for 10 consecutive years, with -$135000.0 as the latest value for Q4 2025.

  • Quarterly Tax Provisions changed N/A to -$135000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$101000.0 through Dec 2025, changed N/A year-over-year, with the annual reading at -$135000.0 for FY2025, N/A changed from the prior year.
  • Tax Provisions for Q4 2025 was -$135000.0 at ImmunityBio, down from -$35000.0 in the prior quarter.
  • The five-year high for Tax Provisions was $269000.0 in Q2 2025, with the low at -$200000.0 in Q1 2025.
  • Average Tax Provisions over 4 years is -$10888.9, with a median of $1000.0 recorded in 2021.
  • The sharpest move saw Tax Provisions soared 3300.0% in 2022, then plummeted 217.65% in 2023.
  • Over 4 years, Tax Provisions stood at $1000.0 in 2021, then skyrocketed by 3300.0% to $34000.0 in 2022, then tumbled by 217.65% to -$40000.0 in 2023, then crashed by 237.5% to -$135000.0 in 2025.
  • According to Business Quant data, Tax Provisions over the past three periods came in at -$135000.0, -$35000.0, and $269000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.